Results 81 to 90 of about 1,164,667 (298)

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Biomarkers

Current Pharmaceutical Design, 2021
Khojasteh, Malekmohammad, Mahmoud, Rafieian-Kopaei   +1 more
openaire   +2 more sources

Definition of valid proteomic biomarkers: a bayesian solution [PDF]

, 2009
Clinical proteomics is suffering from high hopes generated by reports on apparent biomarkers, most of which could not be later substantiated via validation.
Harald Mischak, Mischak, H., Harris, K., Keith Harris, Mark Girolami, Girolami, M.   +5 more
core   +1 more source

Transcriptional profiling of circulating extracellular vesicles from prebiopsy prostate cancer patients

Molecular Oncology, EarlyView.
RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner, Pierre Tennstedt, Randi C. Pose, Christian Müller, Katharina Besler, Svenja Schneegans, Malik Alawi, Marie C. Roesch, Sven Peine, Desiree Bonci, Joanna Budna‐Tukan, Evi Lianidou, Catherine Alix‐Panabières, Derya Tilki, Klaus Pantel   +14 more
wiley   +1 more source

The role of open innovation in biomarker discovery [PDF]

, 2016
Precision medicine aims to treat diseases with special consideration for the individual biological variability. Novel biomarkers (BM) are needed to predict therapeutic responses and to allow for the selection of suitable patients for treatment with ...
Gottwald, Matthias, Matthias Gottwald, Khusru Asadullah, Andreas Busch, Landeck, Lilla, Monika Lessl, Asadullah, Khusru, Lilla Landeck, Busch, Andreas, Lessl, Monika   +9 more
core   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Investigating neonatal health risk variables through cell-type specific methylome-wide association studies

Clinical Epigenetics
Adverse neonatal outcomes are a prevailing risk factor for both short- and long-term mortality and morbidity in infants. Given the importance of these outcomes, refining their assessment is paramount for improving prevention and care.
Thomas L. Campbell, Lin Y. Xie, Ralen H. Johnson, Christina M. Hultman, Edwin J. C. G. van den Oord, Karolina A. Aberg   +5 more
doaj   +1 more source

Platelet protein biomarker panel for ovarian cancer diagnosis [PDF]

, 2018
Background: Platelets support cancer growth and spread making platelet proteins candidates in the search for biomarkers. Methods: Two-dimensional (2D) gel electrophoresis, Partial Least Squares Discriminant Analysis (PLS-DA), Western blot, DigiWest ...
Rui Pinto, Bergstrand, Jan,, Engström, U, Marta Lomnytska, Xu, Lei,, Susanne Becker, Xu, L, Engström, Ulla,, Gustafsson, Sonja, Lei Xu, Bergstrand, Jan, Lomnytska, Marta, Björklund, Christina, Franzén, B, Templin, Markus, Lomnytska, M, Epstein, Elisabeth,, Becker, Susanne,, Sonja Gustafsson, Auer, Gert, Xu, Lei, Pinto, R, Becker, S, Epstein, E, Franzen, Bo,, Pinto, Rui, Elisabeth Epstein, Lomnytska, Marta,, Gustafsson, S, Becker, Susanne, Gert Auer, Widengren, J, Christina Björklund, Jerker Widengren, Markus Templin, Gustafsson, Sonja,, Ulla Engström, Templin, M, Björklund, C, Bergstrand, J, Franzen, Bo, Auer, G, Widengren, Jerker, Pinto, Rui,, Epstein, Elisabeth, Widengren, Jerker,, Templin, Markus,, Engström, Ulla, Auer, Gert,, Bo Franzén, Jan Bergstrand, Björklund, Christina,   +51 more
core   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood‐based biomarkers

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 2016
Introduction There is an urgent need to identify biomarkers that can accurately detect and diagnose Alzheimer's disease (AD). Autoantibodies are abundant and ubiquitous in human sera and have been previously demonstrated as disease‐specific biomarkers ...
Cassandra A. DeMarshall, Eric P. Nagele, Abhirup Sarkar, Nimish K. Acharya, George Godsey, Eric L. Goldwaser, Mary Kosciuk, Umashanger Thayasivam, Min Han, Benjamin Belinka, Robert G. Nagele, Alzheimer's Disease Neuroimaging Initiative   +11 more
doaj   +1 more source